January 3,2023，Aurisco to build an Oligonucleotide FlexFactory™ for commercial cGMP production in cooperation with Cytiva.

In future, Aurisco’s new commercial manufacturing site in Yangzhou, China is expected to produce up to 200 kilograms of cGMP oligonucleotides each year.
Through the cooperation with Cytiva, Aurisco will deliver at least 2 new commercial oligonucleotides per year to its global customers, with high quality and efficiency.

• From left to right: Peng Zhien, Chairman of Aurisco Pharmaceutical Co., Ltd., Li Jinliang, General Manager of Shanghai Aurisco Biotechnology Co., Ltd., Zhou Yun, Director of Cytiva China Enterprise Solutions, and Yu Lihua, General Manager of Cytiva China.
• Li Jinliang, GM of Aurisco’s Biotech CRDMO and Yu Lihua, GM of Cytiva China visiting Aurisco’s R&D labs in Shanghai.Cytiva and Aurisco cooperated to build a flexible factory production line for small nucleic acid in Yangzhou to acceleratethe commercial development of small nucleic acid drugs.

Aurisco cooperates with Cytiva to build its first Oligo FlexFactory for commercial production_Final